Wall Street brokerages expect Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) to report earnings per share (EPS) of ($0.33) for the current quarter, according to Zacks. Zero analysts have issued estimates for Trillium Therapeutics’ earnings. Trillium Therapeutics reported earnings per share of ($0.42) during the same quarter last year, which suggests a positive year-over-year growth rate of 21.4%. The company is expected to announce its next earnings report on Monday, March 9th.
On average, analysts expect that Trillium Therapeutics will report full year earnings of ($1.31) per share for the current fiscal year, with EPS estimates ranging from ($1.43) to ($1.21). For the next financial year, analysts expect that the company will post earnings of ($0.67) per share, with EPS estimates ranging from ($1.04) to ($0.33). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Trillium Therapeutics.
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last released its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.19. The firm had revenue of $0.03 million for the quarter.
Shares of NASDAQ TRIL traded up $0.01 during mid-day trading on Monday, hitting $0.28. 128,800 shares of the stock traded hands, compared to its average volume of 199,756. Trillium Therapeutics has a twelve month low of $0.24 and a twelve month high of $3.20. The company has a market cap of $7.68 million, a PE ratio of -0.12 and a beta of 2.18. The firm has a 50 day simple moving average of $0.28 and a two-hundred day simple moving average of $0.36.
An institutional investor recently raised its position in Trillium Therapeutics stock. Morgan Stanley grew its stake in shares of Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) by 35.8% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 1,045,698 shares of the biotechnology company’s stock after purchasing an additional 275,800 shares during the period. Morgan Stanley owned about 3.73% of Trillium Therapeutics worth $343,000 as of its most recent filing with the SEC. 23.83% of the stock is currently owned by institutional investors and hedge funds.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.